physIQ Partners with Janssen Multi-Year Digital Health Deal

physIQ Announces Strategic Collaboration to Scale Digital Medicine

physIQ, a leader in real-world biosensor data collection and digital biomarkers, today announced a new multi-year collaboration to license physIQ’s accelerateIQTM to Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The relationship allows Janssen to scale the use of biosensors, supporting initiatives across both R&D and commercial strategies. With the license, Janssen will deploy the accelerateIQTM platform to collect data across its clinical studies through a wide variety of wearable biosensors, and capitalize on physIQ’s broad portfolio of FDA-cleared digital biomarkers and medical-grade platform to transform raw data into clinical insight.

Continuous data collected from wearable biosensors represents game-changing potential for biopharma clinical and commercial teams. However, collecting, processing, and analyzing continuously-streaming biosensor data presents technical challenges that, to date, have limited companies’ ability to scale their digital medicine operations. This collaboration reflects the rapid maturation of digital medicine and its strategic clinical implications.

“Continuous real-world sensor data and digital biomarkers are the new frontier of clinical development and pharma commercialization,” said Chris Economos, Chief Commercial Officer of physIQ. “We have built a platform that can accommodate the unknowns of a rapidly-evolving regulated digital medicine landscape – any sensor, any data type, and any algorithm.  We could not be more pleased to work with Janssen as we transform real-world data into real-world insight to deliver solutions for patients, providers, and payers.”

Just as the last decade saw electronic data capture (EDC) and electronic clinical outcome assessment (eCOA) solutions become the standard across all clinical studies, the massive push to decentralized trials and regulatory focus on quality-of-life (QoL) markers have established biosensor data as the new “must have” data set to evaluate safety and efficacy of pharmacotherapies.